Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.
Pfizer has announced that the first-pass analysis of its 'Amaryllis' trial, testing a PDE-10 inhibitor drug, shows the drug did not meet its target of improving Huntington's disease symptoms. As a result, the open-label extension study will be stopped. This is not the news we'd been hoping for, but we've learned a lot about HD along the way.
Our first daily report from the World Congress on Huntington's Disease in Rio de Janeiro, Brazil.
Watch the video of Ed Wild's address to the European Huntington's Association annual meeting in September 2012, summarizing how therapies research works and explaining the most exciting ways researchers are trying to study and treat HD.
At this year's HD therapeutics conference, Pfizer Pharmaceuticals and the CHDI Foundation announced big plans for new HD drugs that target something called 'phosphodiesterases'. What's so exciting about these new drugs, and what's the timeline for bringing them to people?